冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析

目的探讨冠心病患者血浆中凝血酶激活的纤溶抑制物（TAFI）与纤维蛋白原（Fbg）的关系。方法分别应用ELISA法、发色底物法测定40例冠状动脉造影正常者和60例经冠状动脉造影证实的（冠心病CAD）患者血浆中TAFI：Ag、TAFI：A及Fbg的含量。结果CAD患者血浆中TAFI：Ag（95±34％）、TAFI：A（29．2±11．2μg/ml）、Fbg（5．20±2．41g／L）均明显高于冠脉造影正常者（P〈0．001）。结论CAD患者血浆中TAFI：Ag和TAFI：A均显著增高，抑制了Fbg的降解，导致纤溶活性降低。

Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease

Objective To explore the relationship between thrombin activatable fibrinolysis inhibitor （TAFI） and fihrinogen （Fbg） in patients with coronary atherosclerotic heart disease （CAD）. Methods There are 40 healthy adults as controls and 60 CAD patients in the study , all of the people were approved by coronary angiography . The plasma levels of TAFI ： Ag, TAFI ： A and Fbg were examined respectively with enzyme linked immunoadsordent assay （ELISA） or ehrimato-substrate assay. Results The mean of the plasma TAFI：Ag ,TAFI：A and Fbg for CAD patients is 95 ±34% ,29.2 ± 11.2 μg/ml and 5.20 ±2.41g/L,all of these variances are significant as compared with the controls （ P 〈 0. 001 ）. Conclusion The significantly higher plasma TAFI： Ag and TAFI： A in patients with CAD inhibites the degradation for Fbg, then reduces their fibrinolytic activity .